Trial Outcomes & Findings for Optimizing the Ocular Surface Prior to Cataract Surgery (NCT NCT02766907)

NCT ID: NCT02766907

Last Updated: 2019-03-19

Results Overview

Assessed by corneal topography

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

Change from Baseline to 1 month

Results posted on

2019-03-19

Participant Flow

Participant milestones

Participant milestones
Measure
Control
Retrospective review of debridement without cryopreserved amniotic membrane
Study
prospective arm receiving cryopreserved amniotic membrane cryopreserved amniotic membrane: placement of cryopreserved amniotic membrane after routine debridement procedure for epithelial basement membrane dystrophy (EBMD)
Overall Study
STARTED
10
10
Overall Study
COMPLETED
9
9
Overall Study
NOT COMPLETED
1
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Optimizing the Ocular Surface Prior to Cataract Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Study
n=9 Participants
prospective arm receiving cryopreserved amniotic membrane cryopreserved amniotic membrane: placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
Control
n=9 Participants
Retrospective review of debridement without cryopreserved amniotic membrane
Total
n=18 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=39 Participants
1 Participants
n=41 Participants
1 Participants
n=35 Participants
Age, Categorical
>=65 years
9 Participants
n=39 Participants
8 Participants
n=41 Participants
17 Participants
n=35 Participants
Age, Continuous
74 years
STANDARD_DEVIATION 7.5 • n=39 Participants
66.5 years
STANDARD_DEVIATION 5.9 • n=41 Participants
70 years
STANDARD_DEVIATION 7.5 • n=35 Participants
Sex: Female, Male
Female
5 Participants
n=39 Participants
7 Participants
n=41 Participants
12 Participants
n=35 Participants
Sex: Female, Male
Male
4 Participants
n=39 Participants
2 Participants
n=41 Participants
6 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=39 Participants
1 Participants
n=41 Participants
1 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
n=39 Participants
8 Participants
n=41 Participants
17 Participants
n=35 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Region of Enrollment
United States
9 participants
n=39 Participants
9 participants
n=41 Participants
18 participants
n=35 Participants

PRIMARY outcome

Timeframe: Change from Baseline to 1 month

Assessed by corneal topography

Outcome measures

Outcome measures
Measure
Study
n=9 Participants
prospective arm receiving cryopreserved amniotic membrane cryopreserved amniotic membrane: placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
Control
n=9 Participants
Retrospective review of debridement without cryopreserved amniotic membrane
Change in Intraocular Lens Calculation
1.56 D
Standard Deviation 1.6
0.94 D
Standard Deviation 0.7

PRIMARY outcome

Timeframe: Change from Baseline to 1 month

Assessed using biometry and calculated using Holladay I formula

Outcome measures

Outcome measures
Measure
Study
n=9 Participants
prospective arm receiving cryopreserved amniotic membrane cryopreserved amniotic membrane: placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
Control
n=9 Participants
Retrospective review of debridement without cryopreserved amniotic membrane
Change in Intraocular Lens Power Calculation
1.18 D
Standard Deviation 1.2
0.79 D
Standard Deviation 0.5

Adverse Events

Study

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

VP Medical Affairs

TissueTech

Phone: 8882968858

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place